RECORD SHATTERING CLINICAL TRIAL RESULTS ARE PROOF THAT STEM CELL THERAPY IS ABOUT TO TRANSFORM MEDICINE
Clinical trial results like the following are proof that Stem Cell Therapy is about to become the most explosive growth area in medicine.
Trial results prove that Cesca Therapeutics (KOOL) is the most advanced Regenerative Medicine Stem Cell Therapeutics company because they are CONSISTENTLY SUPERIOR to ALL trial results from ALL stem cell therapy trials.
For example: these results are historical in any field of medicine.
Cesca therapeutics recently announced record shattering clinical trial results from their 17 patient CLI trial:
BEFORE treatment, 100% of “No Option” patients required amputation
12 months AFTER treatment, 82.4% of patients had no amputation
Pain level BEFORE treatment on a scale of 0 to 10 was SEVERE at 7.8
Pain level 12 months AFTER treatment was ALMOST NON-EXISTENT at 0.2
6-minute walking distance BEFORE treatment was 14.5 meters
6-minute walking distance 12 months AFTER treatment was 157meters
BEFORE treatment, 11 patients had gangrene with or without ulceration
12 months AFTER treatment 0 patients had gangrene or ulceration
NORMAL NEW BLOOD VESSELS WERE REGENERATED AFTER TREATMENT.
THERE WERE NO ADVERSE SIDE EFFECTS.
CESCA’s AMI, Bone Union and Bone Marrow Stem Cell Transplant studies all show similar successes that are well advanced beyond their peers
If CESCA were trading at ONLY the AVERAGE MARKET CAP of their competitors, CESCA would be selling at $12 per share today.
CESCA is an outstanding opportunity for JNJ to leap into a leading position in stem cell therapy.
CESCA shares are oversold, undervalued and trading at less than $2.00 per share. CESCA is likely to be one of the best performing stocks in investor portfolios for the next few years.